Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

The  2Na+/K+-ATPase is critical for skeletal and heart muscle function in zebrafish

(2012) C. Doganli et al.   JOURNAL OF CELL SCIENCE

CaMKII in the Cardiovascular System: Sensing Redox States

(2011) Jeffrey R. Erickson et al.   PHYSIOLOGICAL REVIEWS

Long-term gemcitabine administration in heavily pretreated Japanese patients with metastatic breast cancer: additional safety analysis of a phase II study

(2011) Shintaro Takao et al.   Breast Cancer

In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762

(2010) J. B. Mitchell et al.   CLINICAL CANCER RESEARCH

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

(2009) H Ueno et al.   BRITISH JOURNAL OF CANCER

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

(2008) N Bucher et al.   BRITISH JOURNAL OF CANCER

Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review

(2008) M. A. Morgan et al.   CLINICAL CANCER RESEARCH

DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

(2008) S. Ashwell et al.   CLINICAL CANCER RESEARCH

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS